Radioactive 'Trojan Horse' drug targets Hard-to-Treat cancers

NCT ID NCT07213791

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new radioactive cancer drug called LY4337713 in adults with advanced solid tumors that have spread. The drug is designed to seek out and deliver radiation directly to cancer cells that have a specific protein marker called FAP. Researchers will primarily check if the treatment is safe, determine the right dose, and see if it helps shrink tumors in people with cancers like pancreatic, breast, ovarian, and others who have already tried other treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam UMC - Locatie VUmc
NOT_YET_RECRUITING

Amsterdam, 1081 HV, Netherlands
BAMF Health Inc.
RECRUITING

Grand Rapids, Michigan, 49503, United States
Barbara Ann Karmanos Cancer Institute
NOT_YET_RECRUITING

Detroit, Michigan, 48201, United States
Baylor College of Medicine
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Biogenix Molecular, LLC
RECRUITING

Miami, Florida, 33165, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Erasmus MC
NOT_YET_RECRUITING

GE Rotterdam, 3015, Netherlands
Fox Chase Cancer Center
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States
Indiana University (IU) School of Medicine
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic - Rochester
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Moffitt
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
NOT_YET_RECRUITING

Amsterdam, 1066 CX, Netherlands
New York University (NYU) Clinical Cancer Center
NOT_YET_RECRUITING

New York, New York, 10016, United States
Stanford University Medical Center
RECRUITING

Stanford, California, 94305, United States
Stichting Radboud Universitair Medisch Centrum
NOT_YET_RECRUITING

Nijmegen, 6525 GA, Netherlands
Texas Oncology - DFW (Sammons CC)
NOT_YET_RECRUITING

Dallas, Texas, 75246, United States
United Theranostics
NOT_YET_RECRUITING

Glen Burnie, Maryland, 21061, United States
Universitaetsklinikum Essen
NOT_YET_RECRUITING

Essen, 45147, Germany
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITING

Utrecht, 3584CX, Netherlands
University of Pennsylvania
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Wisconsin - Carbone Cancer Center
NOT_YET_RECRUITING

Madison, Wisconsin, 53792, United States
Washington University School of Medicine in St. Louis
NOT_YET_RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

BREAST NEOPLASMS CHOLANGIOCARCINOMA COLORECTAL NEOPLASMS ESOPHAGEAL NEOPLASMS OVARIAN NEOPLASMS PANCREATIC INTRADUCTAL NEOPLASMS STOMACH NEOPLASMS